Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.

Cancer immunology, immunotherapy : CII - 1 Feb 2020

Holmström Morten Orebo, Cordua Sabrina, Skov Vibe, Kjær Lasse, Pallisgaard Niels, Ellervik Christina, Hasselbalch Hans Carl, Andersen Mads Hald

Abstract excerpt

There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (CALR) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Transformation, Neoplastic

Share to Disease Susceptibility

Share to Epitopes

Share to Hematologic Neoplasms

Share to Immunomodulation

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 31915854
DOI: 10.1007/s00262-019-02473-y
PMCID: PMC11027882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.PMID 31915854Read ↗

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individualsSemantic proximity Read ↗

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.Semantic proximity Read ↗

Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative NeoplasmsSemantic proximity Read ↗

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.Semantic proximity Read ↗

Calreticulin and cancer.Semantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.Semantic proximity Read ↗

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Semantic proximity Read ↗

Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative NeoplasmsSemantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisSemantic proximity Read ↗

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative NeoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.